215 related articles for article (PubMed ID: 34008122)
21. INSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial Neoplasms.
Rosenbaum JN; Guo Z; Baus RM; Werner H; Rehrauer WM; Lloyd RV
Am J Clin Pathol; 2015 Oct; 144(4):579-91. PubMed ID: 26386079
[TBL] [Abstract][Full Text] [Related]
22. INSM1 is a Sensitive and Specific Marker of Neuroendocrine Differentiation in Head and Neck Tumors.
Rooper LM; Bishop JA; Westra WH
Am J Surg Pathol; 2018 May; 42(5):665-671. PubMed ID: 29438167
[TBL] [Abstract][Full Text] [Related]
23. [Expression of CD200 and INSM1 in gastrointestinal and pancreatic neuroendocrine neoplasms and its diagnostic values].
Cao Z; Cen HB; Wei JG; Qin LZ; Liao W; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2021 Oct; 50(10):1134-1138. PubMed ID: 34619866
[No Abstract] [Full Text] [Related]
24. Diagnostic Value of Insulinoma-Associated Protein 1 (INSM1) and Comparison With Established Neuroendocrine Markers in Pulmonary Cancers.
Staaf J; Tran L; Söderlund L; Nodin B; Jirström K; Vidarsdottir H; Planck M; Mattsson JSM; Botling J; Micke P; Brunnström H
Arch Pathol Lab Med; 2020 Sep; 144(9):1075-1085. PubMed ID: 31913660
[TBL] [Abstract][Full Text] [Related]
25. CytoLyt fixation impedes insulinoma-associated protein 1 (INSM1) immunoreactivity compared to formalin fixation.
Garlin-Politis M; Upadhyay Baskota S; Picon S; Collins N; Virk RK; Cimic A; Yousefi E; Gonzalez A
J Am Soc Cytopathol; 2024; 13(3):213-218. PubMed ID: 38575468
[TBL] [Abstract][Full Text] [Related]
26. INSM1 immunostaining in solid papillary carcinoma of the breast.
Kudo N; Takano J; Kudoh S; Arima N; Ito T
Pathol Int; 2021 Jan; 71(1):51-59. PubMed ID: 33156579
[TBL] [Abstract][Full Text] [Related]
27. INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer.
Razvi H; Tsang JY; Poon IK; Chan SK; Cheung SY; Shea KH; Tse GM
Pathology; 2021 Feb; 53(2):170-178. PubMed ID: 32951906
[TBL] [Abstract][Full Text] [Related]
28. [Expression and significance of INSM1 and SOX11 in pancreatic neuroendocrine tumor and solid pseudopapillary neoplasm].
Cao Z; Cen HB; Zhao JH; Mei J; Qin LZ; Liao W; Ao QL
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Aug; 55(4):575-581. PubMed ID: 37534634
[TBL] [Abstract][Full Text] [Related]
29. The Clinical Significance of Neuroendocrine Features in Invasive Breast Carcinomas.
Lai BS; Tsang JY; Poon IK; Shao Y; Chan SK; Tam FK; Cheung SY; Shea KH; Tse GM
Oncologist; 2020 Sep; 25(9):e1318-e1329. PubMed ID: 32472950
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic Utility of INSM1 in Medullary Thyroid Carcinoma.
Seok JY; Kang M; De Peralta-Venturina M; Fan X
Int J Surg Pathol; 2021 Sep; 29(6):615-626. PubMed ID: 33650906
[TBL] [Abstract][Full Text] [Related]
31. Exploration of INSM1 and hASH1 as additional markers in lung cytology samples of high-grade neuroendocrine carcinoma with indeterminate neuroendocrine differentiation.
Rothrock AT; Stewart J; Li F; Racila E; Amin K
Diagn Cytopathol; 2022 May; 50(5):230-234. PubMed ID: 35147301
[TBL] [Abstract][Full Text] [Related]
32. Immunosensitivity and specificity of insulinoma-associated protein 1 (INSM1) for neuroendocrine neoplasms of the uterine cervix.
Kuji S; Endo A; Kubota M; Uekawa A; Kawakami F; Mikami Y; Koike J; Suzuki N
J Gynecol Oncol; 2023 Jan; 34(1):e1. PubMed ID: 36245222
[TBL] [Abstract][Full Text] [Related]
33. Sonic hedgehog signaling pathway promotes INSM1 transcription factor in neuroendocrine lung cancer.
Chen C; Breslin MB; Lan MS
Cell Signal; 2018 Jun; 46():83-91. PubMed ID: 29501727
[TBL] [Abstract][Full Text] [Related]
34. Neuroendocrine neoplasms of the breast: diagnostic agreement and impact on outcome.
Metovic J; Cascardi E; Uccella S; Maragliano R; Querzoli G; Osella-Abate S; Pittaro A; La Rosa S; Bogina G; Cassoni P; Marchiò C; Sapino A; Castellano I; Papotti M
Virchows Arch; 2022 Dec; 481(6):839-846. PubMed ID: 36243799
[TBL] [Abstract][Full Text] [Related]
35. Syntaxin 1: A Novel Robust Immunophenotypic Marker of Neuroendocrine Tumors.
Kővári B; Turkevi-Nagy S; Báthori Á; Fekete Z; Krenács L
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32059362
[TBL] [Abstract][Full Text] [Related]
36. Well-differentiated rectal neuroendocrine tumors: analysis of histology, including insulinoma-associated protein 1 expression, and biologic behavior, involving a large cohort of 94 cases.
Sappenfield R; Gonzalez IA; Cao D; Chatterjee D
Hum Pathol; 2020 Oct; 104():66-72. PubMed ID: 32763255
[TBL] [Abstract][Full Text] [Related]
37. Clinical Routine Application of the Second-generation Neuroendocrine Markers ISL1, INSM1, and Secretagogin in Neuroendocrine Neoplasia: Staining Outcomes and Potential Clues for Determining Tumor Origin.
Juhlin CC; Zedenius J; Höög A
Endocr Pathol; 2020 Dec; 31(4):401-410. PubMed ID: 32813226
[TBL] [Abstract][Full Text] [Related]
38. Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases.
Kendall Bártů M; Němejcová K; Michálková R; Bui QH; Drozenová J; Fabian P; Fadare O; Hausnerová J; Laco J; Matěj R; Méhes G; Šafanda A; Singh N; Škapa P; Špůrková Z; Stolnicu S; Švajdler M; Lax SF; McCluggage WG; Dundr P
Int J Gynecol Pathol; 2024 Mar; 43(2):123-133. PubMed ID: 37406366
[TBL] [Abstract][Full Text] [Related]
39. Insulinoma-associated protein 1 (INSM1) is a robust marker for identifying and grading pancreatic neuroendocrine tumors.
Kim D; Viswanathan K; Goyal A; Rao R
Cancer Cytopathol; 2020 Apr; 128(4):269-277. PubMed ID: 31977134
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center.
Shafi S; Hu Y; Parwani AV; Ding Q; Li Z
Breast Cancer Res Treat; 2022 Dec; 196(3):463-469. PubMed ID: 36260193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
